Founded in 2013 and headquartered in London, Eleusis is the first clinical-stage life science company dedicated to unlocking the full therapeutic potential of psychedelics through conventional clinical development and regulatory approval.

In 2015 and 2016, Eleusis conducted two clinical trials of lysergic acid diethylamide (LSD). These trials focused on establishing a basic framework for the future clinical development of psychedelics in the context of Alzheimer’s disease and depression.

Eleusis is now embarking on a full clinical development program of ELE-Psilo as a treatment for major depressive disorder. In parallel, Eleusis is continuing its drug discovery and development programs beyond psychiatry in an effort to fully unlock the therapeutic potential of psychedelics. (text from the Eleusis website)



Recently, Beckely Psychtech has acquired Eleusis Therapeutics Limited, strengething its pipeline. Read press release here.

Shlomi Raz, CEO and founder of Eleusis, said: “Beckley have been pioneers in psychedelic science for more than two decades and we are excited to become a part of that story through this transaction. We believe Eleusis represents an excellent acquisition for Beckley Psytech given our shared commitment to developing psychedelic drug therapies for patients in urgent need of new treatment options. I am thrilled to be joining the leadership team at Beckley Psytech as we look to develop meaningful, practical and cost-effective solutions and treatments to these devastating conditions.”


PREVIOUS MindMed NOW Eleusis